Utilization of peptide phage display to investigate hotspots on IL-17A and what it means for drug discovery
Joey Ting(Eli Lilly (United States)), Sepideh Afshar(Eli Lilly (United States)), Christopher Groshong(Eli Lilly (United States)), Michael E. Woodman(Eli Lilly (United States)), Howard B. Broughton(Eli Lilly (Spain)), Frances Tung(Eli Lilly (United States)), Stephen Antonysamy(Eli Lilly (United States)), Feiyu F. Zhang(Eli Lilly (United States)), Danalyn Manglicmot(Eli Lilly (United States)), Alfonso Espada(Eli Lilly (Spain)), Michael J. Chalmers(Scripps Research Institute), Marijane Russell(Center Point), Aiping Zhang(Yangzhou University), Stephen R. Wasserman(Eli Lilly (United States)), Jeffrey A. Dodge(Eli Lilly (United States)), Spencer B. Jones(Princeton University), Jordi Benach(Eli Lilly (United States)), Holly A. Bina(Eli Lilly (United States))
Cited by 24
Related Papers
Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance
|International Journal of Biological Sciences|2022|350
The 2.5 Å Crystal Structure of the SIRT1 Catalytic Domain Bound to Nicotinamide Adenine Dinucleotide (NAD<sup>+</sup>) and an Indole (EX527 Analogue) Reveals a Novel Mechanism of Histone Deacetylase Inhibition
|Journal of Medicinal Chemistry|2013|218
A Multicenter Application and Evaluation of the Oxford Classification of IgA Nephropathy in Adult Chinese Patients
|American Journal of Kidney Diseases|2012|157